The Experts below are selected from a list of 315 Experts worldwide ranked by ideXlab platform
N B Simpson - One of the best experts on this subject based on the ideXlab platform.
-
Sebaceous Hyperplasia in organ transplant recipients shared aspects of hyperplastic and dysplastic processes
Journal of The American Academy of Dermatology, 1996Co-Authors: David De Berker, Aileen Taylor, Anthony G Quinn, N B SimpsonAbstract:Abstract Background: Patients receiving kidney or heart transplants are subject to a wide range of cutaneous changes attributed largely to the immunosuppression required to prevent rejection of their transplant. In addition to infection, they have an increased incidence of dysplastic lesions, some of which are malignant. Objective: Our purpose was to determine the incidence of Sebaceous Hyperplasia in heart and kidney transplant recipients and its association with neoplasia. Methods: Patients undergoing heart transplantation from a single transplant center were examined during a 30-month screening period to establish the prevalence of cutaneous abnormalities. Results: Sixteen of 104 (16%) heart transplant recipients had Sebaceous Hyperplasia in comparison with 1% of an age- and sex-matched control group. Those with Sebaceous Hyperplasia did not have a significantly higher incidence of hypertrichosis than those without Sebaceous Hyperplasia. Conclusion: Sebaceous Hyperplasia is seen in heart transplant recipients. It does not appear to be connected with hypertrichosis, in which it is believed that the piloSebaceous unit is the target of the direct effects of cyclosporine. We propose that the development of Sebaceous Hyperplasia is related to the process of dysplastic epithelial proliferation in transplant recipients.
-
Sebaceous Hyperplasia in organ transplant recipients: shared aspects of hyperplastic and dysplastic processes?
Journal of the American Academy of Dermatology, 1996Co-Authors: David De Berker, Anthony G Quinn, A E Taylor, N B SimpsonAbstract:Patients receiving kidney or heart transplants are subject to a wide range of cutaneous changes attributed largely to the immunosuppression required to prevent rejection of their transplant. In addition to infection, they have an increased incidence of dysplastic lesions, some of which are malignant. Our purpose was to determine the incidence of Sebaceous Hyperplasia in heart and kidney transplant recipients and its association with neoplasia. Patients undergoing heart transplantation from a single transplant center were examined during a 30-month screening period to establish the prevalence of cutaneous abnormalities. Sixteen of 104 (16%) heart transplant recipients had Sebaceous Hyperplasia in comparison with 1% of an age- and sex-matched control group. Those with Sebaceous Hyperplasia did not have a significantly higher incidence of hypertrichosis than those without Sebaceous Hyperplasia. Sebaceous Hyperplasia is seen in heart transplant recipients. It does not appear to be connected with hypertrichosis, in which it is believed that the piloSebaceous unit is the target of the direct effect of cyclosporine. We propose that the development of Sebaceous Hyperplasia is related to the process of dysplastic epithelial proliferation in transplant recipients.
Salvador Gonzalez - One of the best experts on this subject based on the ideXlab platform.
-
Elucidating the pulsed-dye laser treatment of Sebaceous Hyperplasia in vivo with real-time confocal scanning laser microscopy.
Journal of the American Academy of Dermatology, 2020Co-Authors: David Aghassi, Ernesto Gonzalez, Rox R Anderson, Milind Rajadhyaksha, Salvador GonzalezAbstract:Several case reports document successful treatment of Sebaceous Hyperplasia with the pulsed-dye laser. Moreover, noninvasive real-time confocal laser scanning microscopy elucidates the vascular nature of these lesions and their pathophysiologic response to treatment mediated by vessel coagulation. Ten patients with 29 lesions of Sebaceous Hyperplasia were treated with 3 stacked 5-mm pulses of the 585-nm pulsed-dye laser at fluences of 7 or 7.5 J/cm(2). Confocal imaging was performed before and immediately after treatment, as well as at 2, 4, and 8 weeks of follow-up. The great majority of lesions responded to one treatment, with complete disappearance in 28%, decrease in diameter in 66%, and flattening in 93%. Although 28% recrudesced after initial involution, only 7% recurred completely. Three lesions became eroded or crusted, and 7 experienced cutaneous depressions before complete healing, but no scarring or pigmentary side effects were noted. Confocal imaging revealed a prominent "crown" of blood vessels surrounding the Sebaceous duct and coagulation of these vessels with pulsed-dye laser treatment. However, the vessels reappeared during follow-up, and no noticeable morphologic changes in the Sebaceous duct were noted. Vascular targeting of Sebaceous Hyperplasia can be monitored with real-time reflectance confocal microscopy. Most Sebaceous Hyperplasia regresses after one treatment with 3 stacked pulses of the 585-nm pulsed-dye laser. Whether this response is due to temporary ischemia induced by selective vessel destruction or nonspecific thermal diffusion beyond the vessels from pulse stacking has not been determined.
-
elucidating the pulsed dye laser treatment of Sebaceous Hyperplasia in vivo with real time confocal scanning laser microscopy
Journal of The American Academy of Dermatology, 2000Co-Authors: David Aghassi, Ernesto Gonzalez, Rox R Anderson, Milind Rajadhyaksha, Salvador GonzalezAbstract:Abstract Background: Several case reports document successful treatment of Sebaceous Hyperplasia with the pulsed-dye laser. Moreover, noninvasive real-time confocal laser scanning microscopy elucidates the vascular nature of these lesions and their pathophysiologic response to treatment mediated by vessel coagulation. Methods: Ten patients with 29 lesions of Sebaceous Hyperplasia were treated with 3 stacked 5-mm pulses of the 585-nm pulsed-dye laser at fluences of 7 or 7.5 J/cm 2 . Confocal imaging was performed before and immediately after treatment, as well as at 2, 4, and 8 weeks of follow-up. Results: The great majority of lesions responded to one treatment, with complete disappearance in 28%, decrease in diameter in 66%, and flattening in 93%. Although 28% recrudesced after initial involution, only 7% recurred completely. Three lesions became eroded or crusted, and 7 experienced cutaneous depressions before complete healing, but no scarring or pigmentary side effects were noted. Confocal imaging revealed a prominent "crown" of blood vessels surrounding the Sebaceous duct and coagulation of these vessels with pulsed-dye laser treatment. However, the vessels reappeared during follow-up, and no noticeable morphologic changes in the Sebaceous duct were noted. Conclusion: Vascular targeting of Sebaceous Hyperplasia can be monitored with real-time reflectance confocal microscopy. Most Sebaceous Hyperplasia regresses after one treatment with 3 stacked pulses of the 585-nm pulsed-dye laser. Whether this response is due to temporary ischemia induced by selective vessel destruction or nonspecific thermal diffusion beyond the vessels from pulse stacking has not been determined. (J Am Acad Dermatol 2000;43:49-53.)
David De Berker - One of the best experts on this subject based on the ideXlab platform.
-
Sebaceous Hyperplasia in organ transplant recipients shared aspects of hyperplastic and dysplastic processes
Journal of The American Academy of Dermatology, 1996Co-Authors: David De Berker, Aileen Taylor, Anthony G Quinn, N B SimpsonAbstract:Abstract Background: Patients receiving kidney or heart transplants are subject to a wide range of cutaneous changes attributed largely to the immunosuppression required to prevent rejection of their transplant. In addition to infection, they have an increased incidence of dysplastic lesions, some of which are malignant. Objective: Our purpose was to determine the incidence of Sebaceous Hyperplasia in heart and kidney transplant recipients and its association with neoplasia. Methods: Patients undergoing heart transplantation from a single transplant center were examined during a 30-month screening period to establish the prevalence of cutaneous abnormalities. Results: Sixteen of 104 (16%) heart transplant recipients had Sebaceous Hyperplasia in comparison with 1% of an age- and sex-matched control group. Those with Sebaceous Hyperplasia did not have a significantly higher incidence of hypertrichosis than those without Sebaceous Hyperplasia. Conclusion: Sebaceous Hyperplasia is seen in heart transplant recipients. It does not appear to be connected with hypertrichosis, in which it is believed that the piloSebaceous unit is the target of the direct effects of cyclosporine. We propose that the development of Sebaceous Hyperplasia is related to the process of dysplastic epithelial proliferation in transplant recipients.
-
Sebaceous Hyperplasia in organ transplant recipients: shared aspects of hyperplastic and dysplastic processes?
Journal of the American Academy of Dermatology, 1996Co-Authors: David De Berker, Anthony G Quinn, A E Taylor, N B SimpsonAbstract:Patients receiving kidney or heart transplants are subject to a wide range of cutaneous changes attributed largely to the immunosuppression required to prevent rejection of their transplant. In addition to infection, they have an increased incidence of dysplastic lesions, some of which are malignant. Our purpose was to determine the incidence of Sebaceous Hyperplasia in heart and kidney transplant recipients and its association with neoplasia. Patients undergoing heart transplantation from a single transplant center were examined during a 30-month screening period to establish the prevalence of cutaneous abnormalities. Sixteen of 104 (16%) heart transplant recipients had Sebaceous Hyperplasia in comparison with 1% of an age- and sex-matched control group. Those with Sebaceous Hyperplasia did not have a significantly higher incidence of hypertrichosis than those without Sebaceous Hyperplasia. Sebaceous Hyperplasia is seen in heart transplant recipients. It does not appear to be connected with hypertrichosis, in which it is believed that the piloSebaceous unit is the target of the direct effect of cyclosporine. We propose that the development of Sebaceous Hyperplasia is related to the process of dysplastic epithelial proliferation in transplant recipients.
Vichit Leenutaphong - One of the best experts on this subject based on the ideXlab platform.
-
familial presenile Sebaceous gland Hyperplasia
Journal of The American Academy of Dermatology, 1997Co-Authors: Waranya Boonchai, Vichit LeenutaphongAbstract:Sebaceous gland Hyperplasia occurs frequently, particularly in men past middle age. 1 A few cases of Sebaceous gland Hyperplasia have been described in younger age groups. 2-6 Recently, two brothers with premature Sebaceous Hyperplasia were described by Dupre, Bonafe, and Lamon. 5 W e describe a family with premature Sebaceous Hyperplasia in five consecutive generations. The pedigree suggests autosomal dominant inheritance with incomplete penetrance.
Dwight A Scarborough - One of the best experts on this subject based on the ideXlab platform.
-
surgical pearl intralesional electrodesiccation of Sebaceous Hyperplasia
Journal of The American Academy of Dermatology, 2000Co-Authors: Robert S Bader, Dwight A ScarboroughAbstract:From the Division of Dermatology, Department of Internal Medicine, Ohio State University Hospitals. Reprints are not available from the authors. J Am Acad Dermatol 2000;42:127-8. Copyright © 2000 by the American Academy of Dermatology, Inc. 0190-9622/2000/$12.00 + 0 16/74/101938 S ebaceous Hyperplasia is a common, benign proliferation of Sebaceous glands occurring predominantly on the face. Clinically, there is one or several, 2to 4-mm yellowish papules, often with a central umbilication representing the site of a ductal opening. Sebaceous Hyperplasia has been found to occur with an increased frequency in patients receiving hemodialysis1 or immunosuppressive therapy,2,3 especially after kidney transplantation.2 Most often these lesions represent little more than a cosmetic concern, although they may be confused clinically with basal cell carcinoma. Many modalities exist for the treatment of Sebaceous Hyperplasia, including shave excision, electrodesiccation, curettage with electrodesiccation, bichloroacetic or trichloroacetic acid destruction,4 isotretinoin (Accutane) therapy,5,6 cryotherapy,7 carbon dioxide laser ablation, erbium:YAG laser ablation, and pulsed dye laser photothermolysis.8 Unfortunately, treatment of these lesions often result in a depressed scar or are followed by recurrence. Here we adapt a simple procedure, intralesional desiccation,9 for which we have had no clinical scar formation or recurrences in more than 30 treated lesions. Each lesion is anesthetized with approximately 0.3 mL of 1% lidocaine (Xylocaine) with 1:100,000 epinephrine. We use a 733 Birtcher hyfrecator at the 20 setting, which is an intermediate setting, with a fine, noninsulated epilating needle (Fig 1). The needle is inserted into each lobule (Fig 2), one by one, and desiccated for less than 1 second, resulting in a crackling or popping sound. When all visible lobules are treated, a plastic strip (Band-aid) is applied over triple antibiotic ointment (Polysporin). Patients are instructed to continue to apply ointment until completely healed. PEARLS
-
Surgical Pearl: Intralesional electrodesiccation of Sebaceous Hyperplasia ☆ ☆☆ ★
Journal of The American Academy of Dermatology, 2000Co-Authors: Robert S Bader, Dwight A ScarboroughAbstract:From the Division of Dermatology, Department of Internal Medicine, Ohio State University Hospitals. Reprints are not available from the authors. J Am Acad Dermatol 2000;42:127-8. Copyright © 2000 by the American Academy of Dermatology, Inc. 0190-9622/2000/$12.00 + 0 16/74/101938 S ebaceous Hyperplasia is a common, benign proliferation of Sebaceous glands occurring predominantly on the face. Clinically, there is one or several, 2to 4-mm yellowish papules, often with a central umbilication representing the site of a ductal opening. Sebaceous Hyperplasia has been found to occur with an increased frequency in patients receiving hemodialysis1 or immunosuppressive therapy,2,3 especially after kidney transplantation.2 Most often these lesions represent little more than a cosmetic concern, although they may be confused clinically with basal cell carcinoma. Many modalities exist for the treatment of Sebaceous Hyperplasia, including shave excision, electrodesiccation, curettage with electrodesiccation, bichloroacetic or trichloroacetic acid destruction,4 isotretinoin (Accutane) therapy,5,6 cryotherapy,7 carbon dioxide laser ablation, erbium:YAG laser ablation, and pulsed dye laser photothermolysis.8 Unfortunately, treatment of these lesions often result in a depressed scar or are followed by recurrence. Here we adapt a simple procedure, intralesional desiccation,9 for which we have had no clinical scar formation or recurrences in more than 30 treated lesions. Each lesion is anesthetized with approximately 0.3 mL of 1% lidocaine (Xylocaine) with 1:100,000 epinephrine. We use a 733 Birtcher hyfrecator at the 20 setting, which is an intermediate setting, with a fine, noninsulated epilating needle (Fig 1). The needle is inserted into each lobule (Fig 2), one by one, and desiccated for less than 1 second, resulting in a crackling or popping sound. When all visible lobules are treated, a plastic strip (Band-aid) is applied over triple antibiotic ointment (Polysporin). Patients are instructed to continue to apply ointment until completely healed. PEARLS